発症　onset/appearance of disease
発症する　symptoms appear
発症率　an incidence rate
感染　infection 

以下はDr Noor Hisham(保健局長のノール博士)からのコメントだ。

///////////

Sinovac was found to reduce Covid-19 infection by 65.9 per cent, reduce hospitalisation by 87.5 per cent, reduce intensive care unit (ICU) admission by 90.3 per cent and reduce deaths by 86.3 per cent,” he said.

Sinovac:
感染は65%減少　　( infection と書いてあるが　感染じゃなくて発症のことじゃないか？)
入院は87％減少
ICU治療は90%減少
死亡は86%減少

Dr Noor Hisham said in contrast, the Pfizer trial that reported efficacy of 95 per cent was very small and analysed only 170 Covid-19 cases involving a group of eight vaccinated and 162 unvaccinated individuals.

Pfizer:
95%減少　　(多分　発症率のことだろう)

the New England Journal of Medicine published a report on the Sinovac experience in Chile from February to May 2021 on 4.2 million fully vaccinated individuals compared to 5.5 million unvaccinated residents, with the study also having documented 218,784 Covid-19 cases.

情報源　: チリ事例　を　英国医学ジャーナルが取り上げたものを言及

Therefore, he said there is not much difference between the Sinovac and Pfizer vaccines in actual practical use.

“Both are very effective at preventing severe disease and hospitalisation, but less effective against mild or asymptomatic Covid-19,” he added.

Sinovav も　Pfizer も　どちらも　重症化症状(予防)に関しては　大変にワクチン接種効果ある。

ただし　中等症や無症状の予防に関しては　Sinovavの方が　予防効果は劣る。

//////////

このDr Noor のコメントは、デルタ株についての予防効果は言及していない。

以上　(7/21記)